AwardedCzechiaGoodsCZK 146,602,000
Selektivní imunosupresiva - Belatacept II.
- Published
- Published 12 May 2026
- Deadline
- Closed 11 June 2026
Overview
The Czech Institute of Clinical and Experimental Medicine procured selective immunosuppressive drug supplies of belatacept (ATC L04AA28) for parenteral administration for approved patient indications. Bristol-Myers Squibb spol. s r.o. was awarded the contract on 15 June 2026 for 146,601,500 CZK.
Key details
- Country
- Czechia
- Status
- Awarded
- Category
- Goods
- Estimated value
- CZK 146,602,000
- Procedure
- Open
- SME suitable
- Yes
- Published
- 12 May 2026
- Deadline
- Closed
Immunosuppressive agents
Award outcome
- Awarded value
- CZK 146,601,500
- Award date
- 15 June 2026
- Contract period
- — → 25 May 2030
- Bristol-Myers Squibb spol. s r.o.
Contract ending soon? Skim tracks incumbents and flags recompetes early. Book a demo to set up alerts.
Notice history
Every published notice in this contracting process, newest first.
Contract Award Notice
30 June 2026
Contract Notice
11 May 2026
Contracting authority
Institut klinické a experimentální medicíny
Procuring entityPraha, Czechia
Authority website ↗
Get the full picture
AI analysis, bid scoring, and expert strategy for this tender
Skim analyses every tender against your company profile and tells you whether to bid, how to win, and who you are up against.
See which competitors are winning the contracts you're chasing.
15-minute call. We'll pull the win data on your real pipeline and show you what Skim does with it.